Summary of Moderna's Extraordinary General Meeting Company Overview - **Company**: Moderna, Inc. (NasdaqGS:MRNA) - **Event**: 2025 Extraordinary General Meeting - **Date**: November 12, 2025 Key Points Meeting Structure and Procedures - The meeting was chaired by Noubar Afeyan, Chairman of the Board, with CEO Stéphane Bancel and Chief Legal Officer Shannon Klinger present [1][2] - A quorum was confirmed with proxies received for a majority of the shares outstanding as of the record date, September 30, 2025 [4] - Voting was conducted via proxy and virtual ballot, allowing shareholders to change their votes if desired [5] Proposals Discussed - **Proposal One**: Approval of a one-time stock option exchange program for non-executive committee employees - The Board of Directors unanimously recommended approval of this proposal [8] - **Proposal Two**: Approval to adjourn the special meeting to a later date if necessary - The Board also unanimously recommended approval of this proposal [8] Voting Results - Both proposals received the requisite number of votes in favor and were approved by shareholders [10] - Since Proposal One was approved, there was no need to adjourn the meeting [10] - Final voting results will be reported on Form 8-K to be filed with the SEC within four business days [11] Additional Notes - No shareholder questions relevant to the business of the special meeting were received in advance [12] - The meeting concluded with a note of appreciation for shareholder support [12]

Core Insights - Silexion Therapeutics is advancing towards the initiation of Phase 2/3 clinical trials for its RNA interference therapy SIL204, targeting KRAS-driven cancers, with a timeline set for the first half of 2026 [1][2] - The company has successfully raised over $9 million in the third quarter of 2025, significantly improving its financial position [1][5] Clinical Development - Silexion is on track with its operational readiness for the planned Phase 2/3 clinical trials of SIL204, with toxicology studies progressing as scheduled [2] - Regulatory submissions are expected to be filed with the Israel Ministry of Health in Q4 2025 and in Germany and the EU in Q1 2026 [2] - New preclinical data shows SIL204's high efficacy against multiple human cancer cell lines, demonstrating effectiveness against five KRAS-driven cancer types, including pancreatic, lung, colorectal, and gastric cancers [3] Financial Performance - The company raised approximately $9.5 million in gross proceeds during Q3 2025, increasing cash and cash equivalents to $9.2 million, up from $3.5 million at the end of Q2 2025 [5][10] - Shareholders' equity rose to $7.0 million, a significant improvement from a capital deficiency of $4.0 million at year-end 2024 [5] - The net loss for Q3 2025 was $3.3 million, or ($2.88) per share, a decrease of approximately 72.3% compared to a net loss of $11.9 million, or ($274.25) per share, for the same period in 2024 [11] Strategic Partnerships - Silexion has selected AMS Advanced Medical Services GmbH as its contract research organization (CRO) to support the upcoming Phase 2/3 clinical trials, leveraging AMS's extensive experience in oncology clinical development [4] Compliance and Governance - The company has regained compliance with Nasdaq's listing requirements, confirming its continued listing on the Nasdaq Capital Market [6]

Core Viewpoint - Indaptus Therapeutics, Inc. reported its financial results for Q3 2025, highlighting ongoing clinical trials and financial performance, including a recent capital raise of approximately $2.3 million to strengthen its balance sheet [1][2]. Financial Highlights - Research and development expenses for Q3 2025 were approximately $1.52 million, an increase of about $50,000 from $1.47 million in Q3 2024, primarily due to a $0.35 million increase in the ongoing Phase 1 study [3]. - For the nine months ended September 30, 2025, research and development expenses totaled approximately $6.5 million, up by $1.7 million from $4.8 million in the same period in 2024, mainly due to a $2.6 million increase in the Phase 1 study [3]. - General and administrative expenses for Q3 2025 were approximately $1.1 million, a decrease of about $0.6 million from $1.7 million in Q3 2024, primarily due to a reduction in stock-based compensation and payroll-related expenses [4]. - Loss per share for Q3 2025 was approximately $2.98, compared to approximately $9.04 for Q3 2024, indicating a significant reduction in losses [5]. - As of September 30, 2025, the company had cash and cash equivalents of approximately $5.8 million, which is expected to support operations into Q1 2026 [6][7]. Operational Updates - The company completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and tislelizumab, with three participants achieving stable disease at the first assessment [2]. - Enrollment for the trial has been paused pending further efficacy evaluations of remaining participants and to assess future development options [2]. - The company raised approximately $2.3 million in September 2025 through its at-the-market facility, enhancing its financial position [2]. Cash Flow and Financing Activities - Net cash used in operating activities for the nine months ended September 30, 2025, was approximately $11.6 million, compared to $8.9 million for the same period in 2024, primarily due to increased research and development activities [8]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was approximately $11.7 million, significantly higher than $2.9 million for the same period in 2024 [9].

Core Insights - Earnings season presents opportunities for lesser-known companies to gain attention, with three stocks highlighted for potential comebacks if their earnings reports are favorable [2] Company Overview - Scholar Rock Holding Corp. (NASDAQ: SRRK) is a biotech firm focused on developing protein therapeutics for neuromuscular diseases [3] - The lead asset, apitegromab, targets Type 2 and Type 3 Spinal Muscular Atrophy (SMA) and has shown promising Phase 3 data, indicating strong potential for regulatory approval in 2026 [4] Financial Performance - Scholar Rock's shares have declined approximately 33% year-to-date due to manufacturing site issues, raising short-term concerns [4] - The company is projected to report a loss per share of 76 cents for the third quarter, with no revenue expected yet [6] Clinical Development - A Phase 2 study of apitegromab demonstrated over 54% lean mass preservation compared to control when combined with GLP-1 agonist tirzepatide, indicating the drug's therapeutic promise [5] - Investors should look for updates on apitegromab and other drugs in the pipeline during the upcoming earnings report [6] Market Sentiment - Quarterly earnings reports can significantly impact share prices, with Scholar Rock, along with Globant and NiCE, being identified as companies that may see a rebound if they deliver strong earnings [7]

Core Insights - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson's disease and related disorders [2][4] - The company will present a corporate update at the Bell Potter Healthcare Conference on November 19, 2025, for Australian participants and November 18, 2025, for U.S. participants [1][2] - Alterity's lead asset, ATH434, has shown clinically meaningful efficacy in a Phase 2 clinical trial for Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder [2] Company Overview - Alterity Therapeutics is a clinical-stage biotechnology company based in Melbourne, Australia, and San Francisco, California, dedicated to creating treatments for neurodegenerative diseases [2] - The company has a drug discovery platform that generates patentable chemical compounds aimed at treating the underlying pathology of neurological diseases [2] Clinical Development - ATH434 has recently reported positive data from an open-label Phase 2 clinical trial in advanced MSA, indicating progress in the company's drug development program [2] - The company is committed to developing therapies that can modify the course of neurodegenerative diseases, with a specific focus on Parkinson's disease [2]

Core Insights - Artiva Biotherapeutics announced positive initial safety and translational data from clinical trials of AlloNK in combination with anti-CD20 monoclonal antibodies for autoimmune diseases, indicating that AlloNK is well tolerated and effective in B-cell depletion [2][3] Group 1: Treatment Efficacy and Safety - AlloNK, an allogeneic NK cell therapy, demonstrated consistent and complete B-cell depletion in all patients treated by Day 13, comparable to results seen in B-cell driven lymphoma [1][3] - No cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was reported, and the treatment was generally well tolerated with most adverse events being Grade 1 or 2 [1][10] - Among 32 patients treated, all demonstrated non-quantifiable peripheral CD19+ B-cell levels by Day 13, supporting the intended mechanism of action for AlloNK [10] Group 2: Clinical Trials and Future Plans - Artiva is conducting three ongoing Phase 1 and 2 clinical trials for refractory rheumatoid arthritis (RA), Sjögren's disease, and other autoimmune conditions, with plans to share initial clinical response data in the first half of 2026 [3][10] - The company aims to align with the U.S. Food and Drug Administration (FDA) on pivotal trial design for AlloNK in refractory RA in the first half of 2026 [1][10] Group 3: Market Opportunity - There is a significant unmet need for patients with refractory RA who have failed at least two biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/ts DMARDs), representing over 150,000 patients in the U.S. [10] - Current real-world data shows only a 10-20% ACR50 response in patients who have failed two or more b/ts DMARDs, indicating room for improvement with AlloNK [10]

Core Insights - ProMIS Neurosciences Inc. is advancing its lead candidate PMN310 for Alzheimer's disease, with over 85% enrollment in the Phase 1b PRECISE-AD trial and a favorable safety profile reported [1][6][8] - The company has successfully raised capital to support its strategic goals and has strengthened its board with the addition of a new member [2] - Financial results for Q3 2025 show an increase in cash reserves and a significant rise in research and development expenses due to the ongoing clinical trial [5][11] Alzheimer's Disease Program (PMN310) - PMN310 is a humanized IgG1 antibody targeting toxic AβO, which are believed to drive Alzheimer's disease [3][8] - The drug has received Fast Track Designation from the U.S. FDA, indicating its potential to address unmet medical needs in AD [3][8] - The ongoing PRECISE-AD trial is designed to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with interim data expected in Q2 2026 and final results in Q4 2026 [1][9] Financial Highlights - As of September 30, 2025, ProMIS reported cash and cash equivalents of $15.4 million, up from $13.3 million at the end of 2024, primarily due to capital-raising activities [5] - Research and development expenses for Q3 2025 were $9.8 million, a significant increase from $2.6 million in the same period of 2024, reflecting the costs associated with the PRECISE-AD trial [11] - The company reported a loss from operations of $11.8 million for Q3 2025, compared to a loss of $4.4 million in Q3 2024, driven by increased trial expenditures [11][17] Key Pipeline Programs - PMN267, targeting toxic misfolded TDP-43 for amyotrophic lateral sclerosis (ALS), is ready to progress to IND-enabling studies [6] - PMN442, aimed at Parkinson's disease and multiple system atrophy, is also prepared to move forward to IND-enabling studies [6] Company Overview - ProMIS Neurosciences is focused on developing therapeutic antibodies for neurodegenerative diseases, utilizing its proprietary EpiSelect™ platform to identify disease-specific epitopes [7][10] - The company is headquartered in Cambridge, Massachusetts, and Toronto, Ontario, and is committed to addressing the challenges posed by misfolded proteins in various neurodegenerative conditions [7]

Core Insights - Humacyte, Inc. reported total revenues of $753,000 for Q3 2025 and $1,571,000 for the first nine months of 2025, primarily from sales and collaborative research agreements [1][8] - The company is advancing its pipeline with plans for a Biologics License Application (BLA) filing for its acellular tissue engineered vessel (ATEV) in dialysis and initiating first-in-human studies for coronary artery bypass grafting (CABG) [1][3] - Significant sales growth of the Symvess product was noted, with Q3 sales reaching $703,000, a substantial increase from $100,000 in Q2 2025 [3][4] Financial Performance - Revenue for Q3 2025 was $753,000, with $703,000 from U.S. sales of Symvess and $50,000 from a research collaboration [8][19] - The net loss for Q3 2025 was $17.5 million, a decrease from a net loss of $39.2 million in Q3 2024 [13][19] - Research and development expenses decreased to $17.3 million in Q3 2025 from $22.9 million in Q3 2024, attributed to capitalizing costs related to Symvess manufacturing [13][19] Product Development and Pipeline - The company has received 25 Value Analysis Committee (VAC) approvals for Symvess, up from 13 in August 2025, allowing 92 civilian hospitals to purchase the product [4][5] - Positive results from the V007 Phase 3 trial for ATEV in dialysis were presented at Kidney Week 2025, indicating superior duration of use compared to autogenous fistulas [9] - Humacyte plans to submit a supplemental BLA for ATEV in dialysis in the second half of 2026, based on data from ongoing clinical trials [9][19] Intellectual Property and Research - Humacyte expanded its intellectual property portfolio with a new U.S. patent for a bioengineered esophagus, enhancing its existing claims for engineered trachea and urinary conduits [9][19] - The company published multiple studies highlighting the efficacy of Symvess in treating vascular complications, demonstrating high patency rates and limb salvage [4][5]

Core Viewpoint - MeiraGTx Holdings PLC is preparing to release its quarterly earnings, with expectations of negative earnings per share and lower revenues, which may affect investor sentiment [1][2]. Financial Performance - The anticipated earnings per share (EPS) for MGTX is -$0.50, with projected revenue around $6.9 million [2][6]. - The company has a negative P/E ratio of -4.55, indicating negative earnings, and a high price-to-sales ratio of 18.88, suggesting high market expectations for future growth [3][6]. - The enterprise value to sales ratio is 20.15, and the enterprise value to operating cash flow ratio is -5.92, reflecting negative operating cash flow [4]. - The earnings yield is -21.96%, further emphasizing the company's financial difficulties [4]. Debt and Liquidity - MGTX's debt-to-equity ratio is 27.19, indicating a relatively high level of debt compared to its equity [5][6]. - The current ratio is 0.88, suggesting potential liquidity concerns as it is below the standard threshold of 1 [5][6].

Core Viewpoint - Alvotech is expected to report a decline in earnings despite an increase in revenues for the quarter ending September 2025, with significant implications for its stock price based on the upcoming earnings report [2][6] Financial Performance Expectations - Wall Street estimates an earnings per share (EPS) of $0.05 and projected revenue of approximately $118.8 million for the upcoming quarterly earnings release on November 12, 2025 [1] - Analysts predict that if actual results exceed these estimates, the stock may rise, while a miss could lead to a decline in stock value [2] Management and Conference Call - Alvotech's management will hold a conference call on November 13 to discuss financial results and provide updates on pending approvals in the U.S. and Europe, which will be crucial for future earnings projections [3][6] Financial Metrics - The company has a price-to-earnings (P/E) ratio of approximately 24.77, indicating investor willingness to pay for earnings [4][6] - The price-to-sales ratio stands at about 3.10, reflecting the company's market value relative to its sales [4] - The enterprise value to sales ratio is around 5.10, providing insight into the company's valuation compared to its revenue [4] Cash Flow and Financial Structure - The enterprise value to operating cash flow ratio is negative at -67.10, suggesting potential challenges in cash flow generation [5] - The debt-to-equity ratio is notably negative at -7.32, indicating a unique financial structure or potential financial risk [5] - Despite these challenges, the current ratio is 1.82, suggesting the company can cover its short-term liabilities with its short-term assets [5][6]